Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -147.60% is 97% above its 5-year average of -4349.14%, near the high end of its 5-year range (-15464.47%–-147.60%).
As of the fiscal period ended Tuesday, June 30, 2026. 34.07% above its 12-month average of -223.87%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2026 (2026-06-30): -35.78%.
RETURN ON ASSETS (ROA)
-147.60%
RETURN ON ASSETS (ROA) AVG TTM
-223.87%
RETURN ON ASSETS (ROA) AVG 3Y
-1843.76%
RETURN ON ASSETS (ROA) AVG 5Y
-4349.14%
RETURN ON ASSETS (ROA) AVG 10Y
-5198.99%
RETURN ON ASSETS (ROA) AVG 15Y
-4177.31%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+34.07%
CURRENT VS 3Y AVG
+91.99%
CURRENT VS 5Y AVG
+96.61%
CURRENT VS 10Y AVG
+97.16%
CURRENT VS 15Y AVG
+96.47%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.88%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-363.06%
vs the sector median at left
Propanc Biopharma, Inc.
Market Cap
$1.18M
Return on Assets (ROA)
-147.60%
TTM Avg
-223.87%
3Y Avg
-1843.76%
5Y Avg
-4349.14%
Market Cap
$1.15M
Return on Assets (ROA)
-64.99%
TTM Avg
-31.34%
3Y Avg
-98.36%
5Y Avg
-79.15%
Market Cap
$1.11M
Return on Assets (ROA)
-8.84%
TTM Avg
-4.56%
3Y Avg
8.88%
5Y Avg
8.88%
Market Cap
$1.06M
Return on Assets (ROA)
-44.32%
TTM Avg
-57.72%
3Y Avg
-286.30%
5Y Avg
-215.47%
Market Cap
$1.32M
Return on Assets (ROA)
-72.52%
TTM Avg
-80.61%
3Y Avg
-249.55%
5Y Avg
-240.26%
Market Cap
$1.03M
Return on Assets (ROA)
-81.60%
TTM Avg
-1375.39%
3Y Avg
-681.84%
5Y Avg
-547.21%
Market Cap
$1.34M
Return on Assets (ROA)
-96.27%
TTM Avg
-335.81%
3Y Avg
-263.87%
5Y Avg
-193.48%
Market Cap
$1.42M
Return on Assets (ROA)
-247.39%
TTM Avg
-97.35%
3Y Avg
-1378.80%
5Y Avg
-1078.71%
Market Cap
$1.38M
Return on Assets (ROA)
-196.18%
TTM Avg
-334.48%
3Y Avg
-197.38%
5Y Avg
-169.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Propanc Biopharma, Inc. (PPCB) | $1.18M | -147.60% | -223.87% | -1843.76% | -4349.14% |
| IM Cannabis Corp. (IMCC)vs › | $1.15M | -64.99% | -31.34% | -98.36% | -79.15% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | -8.84% | -4.56% | 8.88% | 8.88% |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | -44.32% | -57.72% | -286.30% | -215.47% |
| NewcelX Ltd. (NCEL)vs › | $1.32M | -72.52% | -80.61% | -249.55% | -240.26% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | -81.60% | -1375.39% | -681.84% | -547.21% |
| Genprex, Inc. (GNPX)vs › | $1.34M | -96.27% | -335.81% | -263.87% | -193.48% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.42M | -247.39% | -97.35% | -1378.80% | -1078.71% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | -196.18% | -334.48% | -197.38% | -169.68% |
| NEXGEL, Inc. (NXGL)vs › | $1.43M | -23.39% | -29.27% | -34.02% | -43.63% |
ROA
-147.6%
ROE
-200.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-06-30 | -147.60% |
| 2025-06-30 | -300.14% |
| 2024-06-30 | -2516.41% |
| 2023-06-30 | -4410.89% |
| 2022-06-30 | -3255.32% |
| 2021-06-30 | -15464.47% |
| 2020-06-30 | -4812.32% |
| 2019-06-30 | -5664.42% |
| 2018-06-30 | -9860.34% |
| 2017-06-30 | -8275.04% |
| 2016-06-30 | -2481.92% |
| 2015-06-30 | -544.28% |
| 2014-06-30 | -729.32% |
| 2013-06-30 | -82598.74% |
| 2012-06-30 | -24713.35% |
| 2011-06-30 | -19.90% |
| 2010-06-30 | -1919.66% |
